Financial Performance - The company's revenue for Q3 2025 was ¥89,653,837.13, representing a decrease of 16.21% compared to the same period last year[5] - The net profit attributable to shareholders was a loss of ¥11,880,527.36, a significant decline of 1,258.62% year-over-year[5] - The basic earnings per share for the period was -¥0.09, reflecting an 800.00% decrease compared to the previous year[5] - Total operating revenue for the current period was ¥271,553,589.37, a decrease of 16.6% from ¥325,753,716.96 in the previous period[22] - Net profit for the current period was a loss of ¥30,161,076.91, compared to a loss of ¥2,653,779.13 in the previous period[24] - Basic earnings per share for the current period was -¥0.24, compared to -¥0.02 in the previous period[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,689,365,161.72, down 3.92% from the end of the previous year[5] - The company's total current assets decreased from 677,012,163.72 CNY to 608,393,641.46 CNY, a reduction of approximately 10.14%[18] - The total assets decreased from 1,758,243,932.05 CNY to 1,689,365,161.72 CNY, a decline of about 3.92%[19] - The total liabilities decreased from 1,758,243,932.05 CNY to 1,689,365,161.72 CNY, indicating a reduction in financial obligations[19] - Total liabilities decreased to ¥167,006,178.19 from ¥205,723,871.61, reflecting a reduction of approximately 18.9%[20] - Total equity attributable to shareholders decreased to ¥1,522,358,983.53 from ¥1,552,520,060.44, a decline of about 1.9%[20] Cash Flow - The company reported a cash flow deficit from operating activities of ¥22,789,583.38, a decline of 120.88% year-to-date[5] - Cash flow from operating activities showed a net outflow of ¥22,789,583.38, a significant decline from a net inflow of ¥109,128,879.30 in the previous period[26] - Cash inflow from investment activities increased to ¥728,911,595.04, up from ¥463,146,798.09 in the previous period[26] - Cash flow from financing activities showed a net outflow of $1,224,188.16, compared to a larger outflow of $31,544,611.85 in the previous period, indicating a reduction in financing costs[27] - The net increase in cash and cash equivalents was $172,158.76, contrasting sharply with a substantial increase of $63,558,641.67 in the prior period[27] - The ending balance of cash and cash equivalents stood at $61,953,892.01, down from $194,291,924.17 in the previous period, reflecting a decrease of approximately 68.1%[27] Shareholder Information - Total number of common stock shareholders at the end of the reporting period is 18,134[12] - The largest shareholder, Yang Xining, holds 27.23% of shares, totaling 34,455,650 shares[12] Operational Metrics - The company experienced a 35.32% decrease in accounts receivable financing, primarily due to a reduction in outstanding receivables[9] - The company's other income decreased by 58.18% to ¥4,559,553.75, primarily due to a reduction in government subsidies received[9] - The company reported a significant increase in contract liabilities by 226.70% to ¥2,968,011.02, mainly due to an increase in advance payments received[9] - The company's fixed assets increased by 64.20% to ¥816,687,624.08, attributed to the transfer of construction projects to fixed assets[9] - The inventory increased from 178,882,618.60 CNY to 190,791,788.13 CNY, an increase of approximately 6.14%[18] - The total non-current assets remained relatively stable, decreasing slightly from 1,081,231,768.33 CNY to 1,080,971,520.26 CNY[19] Research and Development - Research and development expenses increased to ¥31,165,593.91, up from ¥28,913,083.62, indicating a focus on innovation[23] Tax and Audit Information - The company reported a significant increase in deferred income tax liabilities, which rose to ¥3,422,861.69 from ¥4,210,778.32, indicating potential future tax obligations[20] - The company did not undergo an audit for the third quarter financial report, which may impact investor confidence[28]
拓新药业(301089) - 2025 Q3 - 季度财报